[Evolving strategies for relapsed multiple myeloma: Toward personalized treatment in 2026].
Multiple myeloma (MM) is a malignant plasma cell disorder whose prognosis has significantly improved with the introduction of proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and more recently BCMA-targeted immunotherapies. In 2026, MM is considered a chronic disease requiring individuali...